Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

On March 11, 2021, Sun Pharmaceutical Industries Inc., USA (Sun Pharma) published results from a five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension. In an analysis of the Phase-3 ReSURFACE 1 and 2 study data, ILUMYA (tildrakizumab-asmn) provided moderate-to-severe plaque psoriasis patients with progressive and maintainable skin clearance with no new safety signals reported through five years of continuous treatment. This is the longest complete dataset of an IL-23 inhibitor reported to date.

Read the full press release

 

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK